Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Gain Therapeutics, Inc. | Director | Common Stock | 290K | $1.12M | $3.86 | Jul 1, 2024 | Direct |
Gain Therapeutics, Inc. | Director | Common Stock | 14.8K | $57.2K | $3.86 | Jul 1, 2024 | By Trust |
NeuBase Therapeutics, Inc. | Director | Stock option (right to buy) | 37.6K | Sep 9, 2022 | Direct | ||
Gain Therapeutics, Inc. | Director | Stock Option (right to buy) | 15K | Jun 24, 2024 | Direct | ||
Gain Therapeutics, Inc. | Director | Restricted Stock Units | 0 | $2.50 | Sep 20, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
GANX | Gain Therapeutics, Inc. | Jul 1, 2024 | 2 | $20.7K | 4 | Jul 1, 2024 | Director |
GANX | Gain Therapeutics, Inc. | Jun 24, 2024 | 1 | $0 | 4 | Jun 26, 2024 | Director |
GANX | Gain Therapeutics, Inc. | Sep 20, 2023 | 2 | $0 | 4 | Sep 22, 2023 | Director |
GANX | Gain Therapeutics, Inc. | Sep 20, 2022 | 2 | $0 | 4 | Sep 22, 2022 | Director |
NBSE | NeuBase Therapeutics, Inc. | Sep 9, 2022 | 1 | $0 | 4 | Sep 12, 2022 | Director |
GANX | Gain Therapeutics, Inc. | May 25, 2022 | 1 | $6.4K | 4 | May 27, 2022 | CHIEF EXECUTIVE OFFICER, Director |
GANX | Gain Therapeutics, Inc. | May 19, 2022 | 2 | $37K | 4 | May 23, 2022 | CHIEF EXECUTIVE OFFICER, Director |
NBSE | NeuBase Therapeutics, Inc. | Mar 1, 2022 | 3 | $6.35K | 4 | Mar 7, 2022 | Director |
NBSE | NeuBase Therapeutics, Inc. | Aug 19, 2021 | 1 | $0 | 4 | Sep 17, 2021 | Director |
GANX | Gain Therapeutics, Inc. | Aug 16, 2021 | 1 | $38.7K | 4/A | Apr 21, 2022 | Chief Executive Officer, Director |
GANX | Gain Therapeutics, Inc. | Mar 17, 2021 | 0 | $0 | 3/A | Apr 21, 2022 | Chief Executive Officer, Director |